Exenatide and the gila monster — how the GLP-1 family started

Nobody was looking for a diabetes drug in gila monster venom. That's not how this discovery started.

John Eng was an endocrinologist at the Bronx VA Medical Center in the 1980s and early 1990s, working in a laboratory that studied peptide hormones in animal venoms and secretions. The work was basic science — the kind of research that doesn't have a product roadmap and doesn't start with a therapeutic target. Eng's laboratory was cataloguing bioactive peptides across a wide range of species, looking for molecules that had physiological relevance. He came to the gila monster because it was known to have unusual metabolic properties, and because its saliva — technically a venom, secreted by glands in the lower jaw — was known to be rich in biologically active peptides.

What he found in the venom was a peptide he eventually called exendin-4. When he mapped its amino acid sequence, it was 53% identical to GLP-1 — glucagon-like peptide-1, the human incretin hormone that the gut releases in response to food. That level of sequence similarity across two species that last shared a common ancestor hundreds of millions of years ago was striking on its own. What made it more striking was what the sequence difference meant for the molecule's behavior in the body.

Human GLP-1 is destroyed within minutes. The enzyme DPP-4 — dipeptidyl peptidase-4 — cleaves the molecule at a specific site near its N-terminus, rendering it inactive almost as soon as it enters circulation. This degradation is so rapid that native GLP-1 was considered essentially undruggable by the pharmaceutical industry: you couldn't inject enough of it fast enough to achieve meaningful plasma concentrations before DPP-4 tore it apart. Exendin-4 had a different sequence at that critical site. DPP-4 couldn't cleave it. In Eng's experiments, exendin-4 bound to the GLP-1 receptor — the same receptor that human GLP-1 binds — and activated it, but it stayed in circulation far longer than the human molecule. Hours instead of minutes.

Eng recognized what this meant and spent years trying to get someone to pay attention to it.

The initial reception was cool. The pharmaceutical industry in the early 1990s was not yet thinking seriously about GLP-1 as a therapeutic target. Eng didn't have the resources of a large lab or a major academic institution behind him — he was working in a VA basement, essentially, with limited staff and limited funding. He filed a patent on exendin-4 and its use as a diabetes treatment in 1992, before most of the field believed GLP-1 was worth pursuing therapeutically. He presented his findings at conferences and encountered skepticism. The molecule looked interesting on paper. It was also completely unprecedented in its origin — a diabetes drug from lizard venom wasn't a category that existed.

The collaboration that eventually turned exendin-4 into a drug happened through Amylin Pharmaceuticals, a San Diego-based biotech that had been founded specifically to pursue the biology of amylin — another pancreatic hormone — but was expanding its metabolic disease portfolio. Amylin licensed Eng's compound and began the development work that would produce exenatide: a synthetic version of exendin-4, identical in sequence, manufactured at pharmaceutical scale and formulated for injection.

The clinical trials confirmed what Eng had found in the laboratory. Exenatide lowered blood sugar in people with type 2 diabetes by the mechanisms that GLP-1 receptor activation produces: it stimulated insulin secretion in a glucose-dependent manner — meaning it boosted insulin when glucose was high but not when it was normal, which avoided hypoglycemia — it suppressed glucagon, and it slowed gastric emptying. It also crossed into the central nervous system and activated GLP-1 receptors in the hypothalamus that regulate appetite and food intake. Patients in the trials lost weight. Not enormous amounts, but consistent, meaningful weight loss that hadn't been expected as a primary effect and couldn't be dismissed as incidental noise.

The FDA approved exenatide as Byetta in April 2005 — the first GLP-1 receptor agonist to reach the market. The indication was type 2 diabetes. The dosing was twice daily, which was a significant burden, and the injection site reactions and nausea that came with the territory made tolerability a challenge for some patients. But it worked. It worked differently than anything that existed before it, through a mechanism that aligned with the body's own post-meal glucose management rather than imposing pharmacological override. And it was followed, in the years after its approval, by every subsequent drug in the class: liraglutide, dulaglutide, semaglutide, tirzepatide. Each one a further refinement of the pharmacological strategy that Eng's discovery made possible.

Amylin and Eli Lilly, which co-promoted Byetta in the United States, eventually extended exenatide into a once-weekly formulation — Bydureon — by encapsulating it in microspheres that degraded slowly over seven days and released the drug in a controlled fashion. The molecule itself was unchanged. What changed was the engineering around it. Bydureon was approved in 2012 and improved adherence substantially.

The gila monster's particular contribution to this story — the DPP-4 resistance built into exendin-4's sequence — is worth appreciating for what it reveals about the relationship between evolutionary biology and pharmacology. The gila monster didn't evolve exendin-4 to be a diabetes drug. It evolved it because its feeding patterns created a selection pressure for durable glucose regulation during long fasting periods, and the solution it landed on happened to be a molecule that activates the same receptor we care about therapeutically and does so without being immediately dismantled by the enzyme that destroys the human version. The overlap between what the lizard needed and what diabetic patients needed wasn't planned. It was discovered by a researcher who was paying attention to the right things at the right time.

This is the part of the story that often gets lost in the marketing of GLP-1 drugs — all of which now carry the clean, abstracted language of pharmaceutical development and none of which advertise their reptilian ancestry. The discovery wasn't funded by a target-based drug development program. It wasn't produced by high-throughput screening of compound libraries. It came from a researcher at a VA hospital cataloguing peptides in animal secretions because he thought it was interesting and potentially important, without knowing exactly what he would find.

The scientific literature is full of molecules that look, in retrospect, like they were waiting to be found: compounds in organisms that have solved biological problems at the molecular level in ways that happen to be relevant to human disease. Marine organisms have produced multiple classes of cancer drugs. Cone snail venom yielded a pain compound. The bacterium that lives in soil near Scottish golf courses gave us lovastatin, the prototype of the statin class. Nature's solutions to the problem of staying alive tend to be biochemically sophisticated in ways that human drug design hasn't always been able to replicate from scratch.

The gila monster's contribution to metabolic medicine didn't end with exenatide. Exendin-4's sequence became a structural template and a proof of concept for the entire GLP-1 agonist class. The demonstration that a DPP-4-resistant GLP-1 receptor agonist could work — that you could achieve durable GLP-1 receptor activation through a molecule that the body's enzyme couldn't immediately inactivate — opened the door to designing human GLP-1 analogs with the same property. Every subsequent modification to liraglutide, semaglutide, and their descendants was pursuing the same goal through different chemistry: keep the molecule in circulation long enough to do its work. The gila monster had already solved that problem. Pharmaceutical chemistry then learned from the solution.

John Eng received recognition for his discovery late and imperfectly, as tends to happen with basic-science findings whose commercial applications take a decade to materialize. He was named a co-inventor on the exenatide patent and eventually received some acknowledgment from the scientific community. The full scale of what his observation produced — a drug class reshaping the treatment of both type 2 diabetes and obesity, currently generating tens of billions of dollars annually, with multiple additional compounds in active development — wasn't visible from a Bronx VA laboratory in 1992.

It rarely is, at the beginning.

The broader implication of the gila monster story isn't just about GLP-1. It's about where pharmaceutical breakthroughs come from and how poorly our funding structures and institutional incentives are calibrated to find them. Basic curiosity-driven research — a researcher asking what's in this venom because the question seems interesting — produces discoveries that target-driven drug development programs wouldn't have found, because target-driven programs need a target before they can begin. Exendin-4 was found before GLP-1 receptor agonism was an established therapeutic concept. The discovery created the concept as much as the concept enabled the discovery.

The gila monster is still in the Sonoran Desert, still managing its glucose through meals that come weeks apart, still carrying the molecular solution that Eng found in its saliva. It doesn't know it changed metabolic medicine. It was just solving the problem of surviving in a desert.